Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Gold seed markers are used to improve the accuracy of radiotherapy to the prostate. By implanting three gold seeds into the prostate we are able to locate its exact position before radiotherapy is delivered, thereby treating less bladder and rectum and minimising the unwanted side effects. These seeds are identified via x-rays. This allows the radiographers to position the treatment couch in a way that ensures more targeted treatment of the prostate by the radiation beams.
| Supplier | Identifier | Award Value | Lots Won | Cross-References |
|---|---|---|---|---|
| Oncology Systems Limited | 03748527 | - | 1 lot Lot 1 | - |
This procurement was divided into 1 lots, each awarded separately. 2 bids were received in total.
| Lot | Value | Bids Received | Awarded To | Status |
|---|---|---|---|---|
| Lot 1 720 days (≈2 yrs) | £150,000 initial term | 2 | Oncology Systems Limited | complete |
Weightings from the notice.
Government spending data: This supplier has received £791,018 in 53 payments (over £25k) from The Christie NHS Foundation Trust, Maidstone and Tunbridge Wells NHS Trust, Royal Cornwall Hospitals NHS Trust, Guy's and St Thomas' NHS FT, University Hospitals Bristol and Weston NHS FT and 1 more public bodies (2022-03-28 to 2026-02-18). View full payment history →
Published by the buyer on this notice. Check the original notice — details change and are not updated here.